title: Are new oral anticoagulant dosing recommendations optimal for all patients?
authors.affiliation: Eshelman School of Pharmacy, University of North Carolina, Chapel Hill.
authors.forename: J Robert
authors.initials: JR
authors.lastname: Powell
mesh_terms: D000284:Administration, Oral; D000925:Anticoagulants / Q000008:administration & dosage*; D000991:Antithrombins / Q000008:administration & dosage; D001562:Benzimidazoles / Q000008:administration & dosage; D000069604:Dabigatran; D065427:Factor Xa Inhibitors / Q000008:administration & dosage*; D006801:Humans; D009025:Morpholines / Q000008:administration & dosage; D011720:Pyrazoles / Q000008:administration & dosage; D011725:Pyridines / Q000008:administration & dosage; D011728:Pyridones / Q000008:administration & dosage; D000069552:Rivaroxaban; D013844:Thiazoles / Q000008:administration & dosage; D013876:Thiophenes / Q000008:administration & dosage; D015091:beta-Alanine / Q000008:administration & dosage / Q000031:analogs & derivatives
chemical_list: D000925:Anticoagulants; D000991:Antithrombins; D001562:Benzimidazoles; D065427:Factor Xa Inhibitors; D009025:Morpholines; D011720:Pyrazoles; D011725:Pyridines; D011728:Pyridones; D013844:Thiazoles; D013876:Thiophenes; D015091:beta-Alanine; C522181:apixaban; D000069552:Rivaroxaban; D000069604:Dabigatran; C552171:edoxaban